Liminatus Pharma, Inc.
LIMN
$1.28
-$0.03-2.29%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | |||
|---|---|---|---|---|---|
| Net Income | 92.12% | -50.00% | 70.30% | ||
| Total Depreciation and Amortization | -- | -- | -- | ||
| Total Amortization of Deferred Charges | -- | -- | -- | ||
| Total Other Non-Cash Items | -- | -- | -- | ||
| Change in Net Operating Assets | -565.21% | 50.00% | -80.53% | ||
| Cash from Operations | -712.81% | -- | 55.80% | ||
| Capital Expenditure | -- | -- | -- | ||
| Sale of Property, Plant, and Equipment | -- | -- | -- | ||
| Cash Acquisitions | -- | -- | -- | ||
| Divestitures | -- | -- | -- | ||
| Other Investing Activities | 48.33% | -- | -17.27% | ||
| Cash from Investing | 48.33% | -- | -17.27% | ||
| Total Debt Issued | 93.75% | -- | -50.00% | ||
| Total Debt Repaid | -- | -- | -- | ||
| Issuance of Common Stock | -- | -- | -- | ||
| Repurchase of Common Stock | -- | -- | -- | ||
| Issuance of Preferred Stock | -- | -- | -- | ||
| Repurchase of Preferred Stock | -- | -- | -- | ||
| Total Dividends Paid | -- | -- | -- | ||
| Other Financing Activities | -7,021.39% | -- | -- | ||
| Cash from Financing | 400.58% | -- | -41.67% | ||
| Foreign Exchange rate Adjustments | -- | -- | -- | ||
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | ||
| Net Change in Cash | 420.23% | -- | -97.82% | ||